###begin article-title 0
###xml 163 166 <span type="species:ncbi:10116">Rat</span>
Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Rat Retinas
###end article-title 0
###begin title 1
OBJECTIVE
###end title 1
###begin p 2
###xml 295 299 <span type="species:ncbi:10116">rats</span>
To elucidate the mechanism of the unique beneficial effect of intravitreal steroid therapy on diabetic macular edema, we investigated the effect of locally administered triamcinolone acetonide (TA) on the expression of vascular endothelial growth factor (VEGF)-A and its receptors in retinas of rats with streptozotocin (STZ)-induced diabetes. We then correlated the expression of these proteins with breakdown of the blood-retinal barrier (BRB).
###end p 2
###begin title 3
RESEARCH DESIGN AND METHODS
###end title 3
###begin p 4
###xml 47 51 <span type="species:ncbi:10116">rats</span>
Thirty-two eyes of 16 diabetic and nondiabetic rats were divided into four groups. TA was injected into the vitreous of the right eye, and saline was injected into the left eye (control) 3.5 weeks after induction of diabetes. Retinas were harvested 48 h following treatment. mRNA and protein expression of VEGF-A, VEGF-A receptor 1 (fms-like tyrosine kinase [FLT]-1), and VEGF-A receptor 2 (fetal liver kinase [FLK]-1) were determined by real-time RT-PCR and immunohistochemistry. BRB permeability was quantitated by measuring extravasated endogenous albumin and retinal thickness.
###end p 4
###begin title 5
RESULTS
###end title 5
###begin p 6
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegf-a</italic>
###xml 268 273 268 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flk-1</italic>
###xml 344 350 344 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegf-a</italic>
###xml 355 360 355 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flk-1</italic>
###xml 395 400 395 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flt-1</italic>
Diabetes-induced retinal thickness and albumin extravasation were significantly reduced in TA-treated diabetic retinas to a level similar to that in sham-treated nondiabetic eyes. A close correlation between albumin leakage and increased expression of both Vegf-a and Flk-1 was noted in the diabetic retinas. TA downregulated the expression of Vegf-a and Flk-1 but upregulated the expression of Flt-1. TA did not alter the expression of these genes in nondiabetic retinas.
###end p 6
###begin title 7
CONCLUSIONS
###end title 7
###begin p 8
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegf-a</italic>
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flk-1</italic>
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flt-1</italic>
Intravitreal injection of TA stabilizes the BRB in association with regulation of Vegf-a, Flk-1, and Flt-1 expression in retinas in the early stages of diabetes.
###end p 8
###begin p 9
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 603 604 603 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
As the prevalence of diabetes progressively rises throughout the world, improving the treatment of macular edema, a common cause of loss of vision from diabetic retinopathy (DR), has become a major goal of ophthalmic research (1). Laser treatment has been proven to reduce the risk of further loss of vision in patients with clinically significant macular edema but is less effective in restoring vision once it already has deteriorated. Moreover, laser treatment is an intrinsically destructive procedure that itself can lead to loss of vision through progressive enlargement of laser scars with time (2).
###end p 9
###begin p 10
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 567 568 567 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 735 736 735 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 539 544 <span type="species:ncbi:9606">human</span>
Breakdown of the blood-retinal barrier (BRB) is an early event in the pathogenesis of DR (3). When local compensatory mechanisms are overcome, frank vasogenic macular edema develops. The anatomical correlate responsible for the BRB is the tight junction-associated proteins between retinal vascular endothelial cells (inner BRB) and retinal pigment epithelial cells (outer BRB). It is strongly suggested that the inner BRB (rather than the outer BRB) is the primary site of the vascular leak that results in diabetic macular edema in both human and animal studies (4,5). In the retinas of rodents, the inner BRB has been shown to become permeable to high-molecular weight molecules in as little as 2 weeks after induction of diabetes (6).
###end p 10
###begin p 11
###xml 207 208 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
Vascular endothelial growth factor (VEGF)-A/vascular permeability factor is believed to mediate increased vascular permeability and colocalize with extravasated albumin in major retinal diseases such as DR (7,8) and age-related macular degeneration (AMD) (9). VEGF-A activates two tyrosine-kinase receptors, fms-like tyrosine kinase-1 (FLT-1, vascular endothelial growth factor receptor-1), and fetal liver kinase-1 (FLK-1, vascular endothelial growth factor receptor-2) (10), which autophosphorylate to initiate a signaling cascade that results in increased microvascular permeability and angiogenesis (11). Inhibition of the VEGF-A overexpression is thus a potential treatment for DR and AMD (12,13).
###end p 11
###begin p 12
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 298 304 <span type="species:ncbi:9986">rabbit</span>
###xml 324 327 <span type="species:ncbi:10116">rat</span>
Triamcinolone acetonide (TA) is an intermediate acting corticosteroid suspension. Intravitreal injections of TA (IVTA) have shown remarkable efficacy for the treatment of advanced DR, in particular diabetic macular edema (14,15). IVTA has been shown to inhibit VEGF-induced breakdown of the BRB in rabbit and leukostasis in rat models of DR (16,17). In a 2-year, double-masked, placebo-controlled, randomized clinical trial, eyes with recalcitrant diabetic macular edema involving the fovea that were treated with IVTA had twice the chance of improving vision and half the risk of further loss. However, a high incidence of cataract and elevated intraocular pressure was found in IVTA-treated eyes (18). If the unique beneficial effect of intravitreal steroid therapy on macular edema is to be distinguished from its high risk of local adverse events (glaucoma and cataract), the precise mechanism of action of TA needs to be elucidated. In this study, we determined the effect of IVTA on the expression of VEGF-A and its receptors in a rodent model of early DR.
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin title 14
Animals.
###end title 14
###begin p 15
###xml 25 29 <span type="species:ncbi:10116">rats</span>
Male Sprague-Dawley (SD) rats (aged 8-10 weeks, ARC Laboratories, Perth, Australia), weighing 240-250 g, were used in this study. The animals were cared for in accordance with The Association for Research in Vision and Ophthalmology statement for the use of animals in ophthalmic and vision research. All animals were housed with environmental enrichment with free access to food and water. Experimental procedures were conducted under aseptic conditions and were approved by the Animal Ethics Committee of the University of Sydney.
###end p 15
###begin title 16
Induction of diabetes.
###end title 16
###begin p 17
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 61 65 <span type="species:ncbi:10116">rats</span>
###xml 137 141 <span type="species:ncbi:10116">Rats</span>
###xml 271 275 <span type="species:ncbi:10116">rats</span>
###xml 579 583 <span type="species:ncbi:10116">Rats</span>
Diabetes was induced with streptozotocin (STZ) (Sigma) in SD rats according to the published protocol with slight modifications (19,20). Rats were given a single dose of 65 mg/kg STZ i.p. in 100 mmol/l citrate buffer (pH 4.5); weight- and age-matched nondiabetic control rats received vehicle only. Eight animals were used per group for each set of experiments. After STZ injection, body weights were recorded daily, and diabetic status was confirmed by tail vein blood glucose estimation using an automated Accu-Chek glucometer (Roche Diagnostics, Indianapolis, IN) after 48 h. Rats with nonfasting blood glucose levels >13.8 mmol/ml were deemed diabetic; those with lower values were excluded from this study. Maintenance of a diabetic state was confirmed by weekly tail vein blood glucose measurements.
###end p 17
###begin title 18
Treatment.
###end title 18
###begin p 19
###xml 219 220 219 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 153 237 153 237 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="20">Diabetic eyes with IVTA treatment (IVTA-treated diabetic retinas, <italic>n</italic> = 8, right eyes)</p>
###xml 153 237 153 237 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="20">Diabetic eyes with IVTA treatment (IVTA-treated diabetic retinas, <italic>n</italic> = 8, right eyes)</p></list-item>
###xml 303 304 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 237 320 237 320 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="21">Diabetic eyes with sham treatment (sham-treated diabetic retinas, <italic>n</italic> = 8, left eyes)</p>
###xml 237 320 237 320 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="21">Diabetic eyes with sham treatment (sham-treated diabetic retinas, <italic>n</italic> = 8, left eyes)</p></list-item>
###xml 392 393 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 320 410 320 410 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="22">Nondiabetic eyes with IVTA treatment (IVTA-treated nondiabetic retinas, <italic>n</italic> = 8, right eyes)</p>
###xml 320 410 320 410 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="22">Nondiabetic eyes with IVTA treatment (IVTA-treated nondiabetic retinas, <italic>n</italic> = 8, right eyes)</p></list-item>
###xml 482 483 482 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 410 500 410 500 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="23">Nondiabetic eyes with sham treatment (sham-treated nondiabetic retinas, <italic>n</italic> = 8, left eyes).</p>
###xml 410 500 410 500 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="23">Nondiabetic eyes with sham treatment (sham-treated nondiabetic retinas, <italic>n</italic> = 8, left eyes).</p></list-item>
###xml 153 500 153 500 <list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" list-type="order"><list-item><p textid="20">Diabetic eyes with IVTA treatment (IVTA-treated diabetic retinas, <italic>n</italic> = 8, right eyes)</p></list-item><list-item><p textid="21">Diabetic eyes with sham treatment (sham-treated diabetic retinas, <italic>n</italic> = 8, left eyes)</p></list-item><list-item><p textid="22">Nondiabetic eyes with IVTA treatment (IVTA-treated nondiabetic retinas, <italic>n</italic> = 8, right eyes)</p></list-item><list-item><p textid="23">Nondiabetic eyes with sham treatment (sham-treated nondiabetic retinas, <italic>n</italic> = 8, left eyes).</p></list-item></list>
###xml 94 98 <span type="species:ncbi:10116">Rats</span>
Intravitreal treatment with TA or saline was performed 3.5 weeks after induction of diabetes. Rats were divided into four experimental treatment groups: Diabetic eyes with IVTA treatment (IVTA-treated diabetic retinas, n = 8, right eyes)Diabetic eyes with sham treatment (sham-treated diabetic retinas, n = 8, left eyes)Nondiabetic eyes with IVTA treatment (IVTA-treated nondiabetic retinas, n = 8, right eyes)Nondiabetic eyes with sham treatment (sham-treated nondiabetic retinas, n = 8, left eyes).
###end p 19
###begin p 20
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Diabetic eyes with IVTA treatment (IVTA-treated diabetic retinas, n = 8, right eyes)
###end p 20
###begin p 21
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Diabetic eyes with sham treatment (sham-treated diabetic retinas, n = 8, left eyes)
###end p 21
###begin p 22
###xml 72 73 72 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Nondiabetic eyes with IVTA treatment (IVTA-treated nondiabetic retinas, n = 8, right eyes)
###end p 22
###begin p 23
###xml 72 73 72 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Nondiabetic eyes with sham treatment (sham-treated nondiabetic retinas, n = 8, left eyes).
###end p 23
###begin title 24
Intravitreal injection of TA.
###end title 24
###begin p 25
###xml 663 665 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
STZ-induced diabetic or nondiabetic animals were anesthetized by isoflurane inhalation and a 4:1 mixture of ketamine hydrochloride (80 mg/kg) and xylazine hydrochloride (4 mg/kg) i.m. Pupils were dilated with one drop each of 0.5% tropicamide and 2.5% phenylephrine hydrochloride. For additional topical anesthesia, 0.4% benoxinate-HCl of eye drop was applied followed by 0.5% of levofloxacin ophthalmic solution to prevent infection. A single dose of 56 mug TA (Kenacort-A 40, Victoria, Australia) in a volume of 5.6 mul (10 mg/ml) was injected into the vitreous of the right eye with a 32-gauge microinjector (Hamilton, Reno, NV) under a dissecting microscope (17). The contralateral eye, which received an equal volume of saline, served as a sham-treated control. A 30-gauge needle was used to make a punch incision 1 mm posterior to the temporal limbus, and a microinjector needle was then inserted through the incision, approximately1.5 mm deep, angled toward the optic nerve.
###end p 25
###begin title 26
Preparation of retinas for histopathology/immunohistochemistry and real-time RT-PCR.
###end title 26
###begin p 27
###xml 200 203 <span type="species:ncbi:10116">rat</span>
###xml 627 631 <span type="species:ncbi:10116">rats</span>
To detect VEGF-A, FLT-1, or FLK-1 antigen, the chest cavity was opened following anesthesia as described above. A 20-gauge perfusion cannula was introduced into the aorta via the left ventricle. Each rat was perfused with 60 ml PBS at 37degreesC to clear the retinal vessels then perfused with 40 ml 2% paraformaldehyde (PFA) in 0.1 mol/l phosphate buffer (PBS), pH 7.4, after achieving drainage from the right atrium. Eyes were collected and fixed in 2% PFA overnight at 4degreesC. The fixed eyes were processed routinely and embedded in paraffin wax. To quantitate BRB breakdown (immunochemical analysis of albumin leakage), rats were killed without perfusion.
###end p 27
###begin p 28
For real-time RT-PCR studies, each retina was dissected and frozen immediately in liquid nitrogen after perfusion with 100 ml PBS. Retinas were stored at -80degreesC until extraction of RNA.
###end p 28
###begin title 29
RNA isolation and characterization.
###end title 29
###begin p 30
###xml 209 212 209 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">260</sub>
###xml 214 217 214 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">280</sub>
###xml 223 226 223 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">260</sub>
###xml 228 231 228 231 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">230</sub>
Total RNA was isolated from individual retinas using TRI reagent (Sigma) and purified with a RNeasy Mini kit (Qiagen, Victoria, Australia) according to the manufacturer's instructions. RNA concentrations and A260/A280 and A260/A230 ratios were measured using a NanoDrop spectrophotometer. RNA integrity was assessed with an Agilent 2100 Bioanalyzer using an Agilent RNA 6000 Nano LabChip kit (Agilent Technologies, Palo Alto, CA).
###end p 30
###begin title 31
Two-step real-time RT-PCR.
###end title 31
###begin p 32
Reverse transcription (RT) was carried out using a SuperScript III First-Stand Synthesis System for RT-PCR kit (Invitrogen, Australia). RNA (1 mug) was reverse transcribed using 2.5 mumol/l Oligo(dT) primer after DNase I treatment according to the manufacturer's instructions. A non-RT control (minus RT) was performed for each RNA sample to test genomic DNA contamination. The RT reaction was performed at 50degreesC for 50 min after denaturing at 65degreesC for 5 min. The RT reactions were terminated by incubation at 85degreesC for 5 min.
###end p 32
###begin p 33
###xml 674 681 644 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 616 619 <span type="species:ncbi:10116">rat</span>
Real-time PCR was performed using a Platinum SYBR Green qPCR SuperMix-UDG kit (Invitrogen, Australia) on a Rotor-Gene 3000 real-time thermal cycler according to the manufacturer's instruction. The same real-time PCR cycling condition was used for all target genes: 50degreesC for 2 min (UDG reaction), 95degreesC for 2 min, 45 cycles of 95degreesC, 15 s; 60degreesC 20 s; 72degreesC 20 s. Melting curve analysis and agarose gel electrophoresis were performed to confirm the purity of the qPCR products. All samples were performed in duplicate, and replicate data were collected for further comparative analysis. The rat gene specific primer pairs used for PCR are listed in Table 1.
###end p 33
###begin p 34
Primers and product size for real-time RT-PCR
###end p 34
###begin p 35
###xml 48 51 <span type="species:ncbi:10116">rat</span>
The pairs of primers were designed according to rat gene sequences published in GenBank.
###end p 35
###begin title 36
Relative quantification and statistical analysis.
###end title 36
###begin p 37
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gapdh</italic>
###xml 133 138 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">actin</italic>
The BestKeeper program () was used to determine the better reference gene between two widely used housekeeping genes (Gapdh and beta-actin) for our study.
###end p 37
###begin p 38
###xml 267 268 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The relative quantification analysis was performed using the Relative Expression Software Tool (REST-MCS). The statistical significance of variations in gene expression was analyzed by the pairwise fixed reallocation randomization test provided by the REST software. P values <0.05 were considered significant. Data are shown as means +/- SEM.
###end p 38
###begin title 39
Morphological analysis.
###end title 39
###begin p 40
###xml 641 644 <span type="species:ncbi:10116">rat</span>
Retinal thickness was evaluated by using Image-Pro Plus (IPP) 4.5 (Media Cybernetics, Silver Spring, MD) on 5 mum hematoxylin and eosin-stained sections. The eyes were cut vertically through the center of the cornea and optic nerve, and both halves were embedded face down. Care was taken to keep this cutting angle consistent for all eyes measured for retinal thickness. Images of retinal sections were obtained, and the thickness of both the retinas and sclera was measured using IPP4.5 with a reference micrometer (Olympus, Australia) under the same conditions. Twenty lines were manually drawn by an observer masked to the status of the rat from which the eye was obtained, from the inner limiting membrane to the tips of the photoreceptor outer segments for each of 20 sequential fields. The mean scleral width was also calculated and found to be similar among the four groups, indicating that differences in retinal thickness were not due to systematic sampling error (not shown).
###end p 40
###begin title 41
Immunohistochemical detection of retinal VEGF-A, FLK-1, FLT-1, and albumin.
###end title 41
###begin p 42
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 252 253 251 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 254 255 253 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Standard indirect immunohistochemical methods were used to detect leakage of albumin and the expression of VEGF-A, FLK-1, and FlT-1 (21). The paraffin-embedded retinal sections (5 mum) were dewaxed and dehydrated. The sections were then quenched with H2O2 blocker (Dako, Australia) for 10 min at room temperature and washed three times in Tris-buffered saline (TBS), pH 7.6.
###end p 42
###begin p 43
###xml 82 87 <span type="species:ncbi:9940">sheep</span>
###xml 93 98 <span type="species:ncbi:9606">human</span>
###xml 242 248 <span type="species:ncbi:9986">rabbit</span>
###xml 254 259 <span type="species:ncbi:9940">sheep</span>
For detection of albumin leakage in the retinas, the sections were incubated with sheep anti-human albumin polyclonal antibody (Abcam, Cambridge, U.K.) at a 1:500 dilution for 1 h at room temperature. The sections were further incubated with rabbit anti-sheep HRP-Streptavidin immunoglobulin (Abcam) for 30 min at room temperature after three washes with TBS. The sections were developed with 3-amino-9-ethylcarbazole chromogen (AEC; Dako) for 3 min and counterstained with hematoxylin.
###end p 43
###begin p 44
###xml 199 200 193 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 201 202 195 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 241 247 <span type="species:ncbi:9986">rabbit</span>
###xml 253 258 <span type="species:ncbi:9606">human</span>
###xml 422 426 <span type="species:ncbi:9925">goat</span>
###xml 432 438 <span type="species:ncbi:9986">rabbit</span>
For detection of VEGF-A, FLK-1, and FLT-1, the sections were treated with antigen retrieval solution (Dako) at 90degreesC for 10 min, subsequently cooled to room temperature, and then quenched with H2O2 blocker. Sections were incubated with rabbit anti-human polyclonal primary antibody [VEGF-A (1:100); FLK-1 (1:200) or FLT-1 (1:50) antibody] (Abcam) for 1 h at room temperature. The sections were further incubated with goat anti-rabbit HRP-Streptavidin immunoglobulin (Abcam) for 30 min at room temperature. Slides were developed with diaminobenzidine (DAB; Dako) for 5 min and counterstained with hematoxylin.
###end p 44
###begin p 45
An isotype-matched negative control was used for all the antibodies (data not shown).
###end p 45
###begin title 46
Quantification and statistical analysis of immunohistochemical staining.
###end title 46
###begin p 47
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 839 841 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
The peroxidase activity was visualized using DAB. The numbers of VEGF-A-, FLT-1 -, and FLK-1-positive stained cells were counted per high- power field (400x) by using IPP4.5 as described previously (22,23). Briefly, the threshold of positive signal was defined for each antibody for all the sections following different treatments. Color signal above the threshold for each antibody defined was deemed to be positive, whereas any signal below the threshold was regarded as negative. Analyses consisted of 20 fields per retina. The entire retina was measured with reference to a micrometer (Olympus) under the same condition sequentially. The number of positive signals versus total cell numbers within each field of the retina was determined with IPP 4.5 and was expressed as positive cell numbers per millimeter, as described previously (24).
###end p 47
###begin p 48
Extravasated albumin was visualized with AEC Chromogen. The threshold of positive staining of albumin was defined for all sections before automate counting. The intravascular space was excluded by the analysis. The ratio of the area of positive signal versus the total retinal area in each field was determined with IPP 4.5 and expressed as image arbitrary units (IAUs). All images analyzed with IPP 4.5 were evaluated by an experienced masked histopathologist.
###end p 48
###begin title 49
Statistics for immunostaining.
###end title 49
###begin p 50
###xml 176 177 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
All data are presented as means +/- SEM. One-way ANOVA was performed for statistical analysis (GraphPad Prism Version 4.0, San Diego, CA). Differences between group means with P values of <0.05 were regarded as being statistically different.
###end p 50
###begin title 51
RESULTS
###end title 51
###begin title 52
Retinal gene transcription of Vegf-a, Flk-1, and Flt-1.
###end title 52
###begin title 53
Total RNA yield and quality.
###end title 53
###begin p 54
###xml 107 110 107 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">260</sub>
###xml 112 115 112 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">280</sub>
###xml 121 124 121 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">260</sub>
###xml 126 129 126 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">230</sub>
###xml 442 443 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The average yields of total RNA extracted from retinas in different groups were comparable. The ratios of A260/A280 and A260/A230 for all RNA samples were above 2 (2.10 +/- 0.005 and 2.03 +/- 0.002, respectively), indicating limited protein and organic contaminants. RNA integrity number (RIN), obtained automatically by the Agilent 2100 Expert software, was similar between the diabetic and nondiabetic groups (8.7 +/- 0.2 vs. 8.4 +/- 0.01, P = 0.88).
###end p 54
###begin p 55
A single PCR fragment was obtained for each gene-specific primer pair with the expected length as determined by 1.5% agarose gel electrophoresis. This was confirmed with a unique peak in the melting curve analysis for each real-time PCR reaction (data not shown).
###end p 55
###begin p 56
###xml 5 10 2 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">actin</italic>
###xml 115 123 112 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Tables 2</xref>
###xml 128 129 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
beta-actin was selected as a reference gene for this study based on the results obtained from BestKeeper software (Tables 2 and 3).
###end p 56
###begin p 57
Results from BestKeeper descriptive statistical analysis showing variation in the capability potential (CP) values
###end p 57
###begin p 58
Housekeeping gene expressions were assessed on total RNA templates isolated from retinas. GM (CP), the geometric mean of CP; AM (CP), the arithmetic mean of CP; Min (CP) and Max (CP), the extreme values of CP; SD (+/-CP), the SD of the CP; CV (%CP), the coefficient of variance expressed as a percentage of the CP level.
###end p 58
###begin p 59
Results from BestKeeper correlation analysis
###end p 59
###begin p 60
Measures of correlation between the two candidate gene expressions and the Bestkeeper in an index computed from the best candidate genes.
###end p 60
###begin title 61
Relative changes in Vegf-a, Flk-1, and Flt-1 mRNA expression.
###end title 61
###begin p 62
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegf-a</italic>
###xml 115 121 115 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegf-a</italic>
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flk-1</italic>
###xml 183 189 183 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegf-a</sub>
###xml 182 189 182 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Vegf-a</sub></italic>
###xml 203 208 203 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flk-1</sub>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Flk-1</sub></italic>
###xml 237 242 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flt-1</italic>
###xml 272 277 272 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flt-1</sub>
###xml 271 277 271 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Flt-1</sub></italic>
###xml 368 374 368 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 374 375 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 378 384 378 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegf-a</italic>
###xml 389 394 389 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flk-1</italic>
###xml 475 481 475 481 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegf-a</sub>
###xml 474 481 474 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Vegf-a</sub></italic>
###xml 495 500 495 500 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flk-1</sub>
###xml 494 500 494 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Flk-1</sub></italic>
###xml 520 525 520 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flt-1</italic>
###xml 567 572 567 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flt-1</sub>
###xml 566 572 566 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Flt-1</sub></italic>
###xml 603 609 603 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 609 610 609 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 687 693 687 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegf-a</italic>
###xml 698 712 698 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flk-1 or Flt-1</italic>
###xml 772 778 772 778 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegf-a</sub>
###xml 771 778 771 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Vegf-a</sub></italic>
###xml 789 794 789 794 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flk-1</sub>
###xml 788 794 788 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Flk-1</sub></italic>
###xml 809 814 809 814 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flt-1</sub>
###xml 808 814 808 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Flt-1</sub></italic>
###xml 825 831 825 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 831 832 831 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
Diabetes and TA treatment differentially regulated the transcription of Vegf-a and its receptors. Transcription of Vegf-a and Flk-1 was significantly increased by 2.5- and 1.8-fold (PVegf-a = 0.001 and PFlk-1 = 0.031), respectively, but Flt-1 was downregulated 4.3-fold (PFlt-1 = 0.005) in sham-treated diabetic retinas compared with sham-treated nondiabetic retinas (Fig. 1A). Vegf-a and Flk-1 transcription was significantly downregulated 2.9- and 2.0-fold, respectively (PVegf-a = 0.030 and PFlk-1 = 0.028); however, Flt-1 was significantly upregulated 1.3-fold (PFlt-1 = 0.002) with IVTA treatment (Fig. 1B). There was no statistically significant difference in the transcription of Vegf-a and Flk-1 or Flt-1 between sham-treated and IVTA-treated nondiabetic groups (PVegf-a = 0.519, PFlk-1 = 0.679, and PFlt-1 = 0.909) (Fig. 1C).
###end p 62
###begin p 63
###xml 27 40 27 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegf-a, Flk-1</italic>
###xml 45 53 45 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flt-1. A</italic>
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 179 180 179 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
mRNA expression ratios for Vegf-a, Flk-1 and Flt-1. A: Sham-treated diabetic retina/sham-treated nondiabetic retina. B: IVTA-treated diabetic retina/sham-treated diabetic retina. C: IVTA-treated nondiabetic retina/sham-treated nondiabetic retina.
###end p 63
###begin title 64
Retinal protein expression of VEGF-A, FLK-1, and FLT-1.
###end title 64
###begin p 65
###xml 470 471 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 727 728 719 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 739 745 731 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 745 746 737 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 949 950 937 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1184 1185 1168 1169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1197 1203 1181 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 1203 1204 1187 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 1373 1374 1353 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1386 1392 1366 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 1392 1393 1372 1373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1596 1597 1572 1573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1609 1615 1585 1591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 1615 1616 1591 1592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1815 1816 1783 1784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1999 2000 1967 1968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2000 2006 1968 1974 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF-A</sub>
###xml 2017 2018 1985 1986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2018 2023 1986 1991 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLK-1</sub>
###xml 2038 2039 2006 2007 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2039 2044 2007 2012 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT-1</sub>
###xml 2056 2062 2024 2030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 2062 2065 2030 2033 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;C</italic>
The expression of VEGF-A and its two receptors (FLK-1 and FLT-1) was found predominantly in the ganglion cell layer, inner nuclear layer, and outer plexiform layer of all four treatment groups. In nondiabetic retinas, immunoreactivity against VEGF and FLK-1 was weak in these layers in contrast to that in the diabetic retinas. The expression of VEGF-A was increased by 1.8-fold in the sham-treated diabetic retinas (37.44 +/- 0.74 vs. 20.40 +/- 0.44 positive cells/mm, P < 0.0001) compared with sham-treated nondiabetic retinas. The number of VEGF-A-positive cells was reduced by 32.1% in the IVTA-treated diabetic retinas in contrast to the sham-treated diabetic retinas (25.41 +/- 0.62 vs. 37.44 +/- 0.74 positive cells/mm, P < 0.001) (Fig. 2A). Similarly, FLK-1 expression was increased by 1.6-fold in the sham-treated diabetic retinas compared with that in sham-treated nondiabetic retinas (53.17 +/- 1.08 vs. 32.95 +/- 0.47 positive cells/mm, P < 0.0001). The number of FLK-1-positive cells was significantly decreased by 28.5% in the diabetic retinas with IVTA treatment compared with that in sham-treated diabetic retinas (37.99 +/- 0.71 vs. 53.17 +/- 1.08 positive cells/mm, P < 0.0001) (Fig. 2B). In contrast to the elevated levels of VEGF and FLK-1, FLT-1 expression was reduced by 37.5% in diabetic retinas (16.94 +/- 0.76 vs. 27.09 +/- 0.56 positive cells/mm, P < 0.0001) (Fig. 2C). The number of FLT-1-positive cells in IVTA-treated diabetic retinas increased by 1.2-fold compared with that in the sham-treated diabetic retinas (20.87 +/- 0.73 vs. 16.94 +/- 0.76 positive cells/mm, P = 0.0002) (Fig. 2C) but was still significantly less than both TA-treated or sham-treated nondiabetic retinas (20.87 +/- 0.73 vs. 26.53 +/- 0.67 positive cells/mm; 20.87 +/- 0.73 vs. 27.09 +/- 0.56 positive cells/mm, P < 0.0001 for both). No significant difference was detected in the expression of VEGF-A and its receptors (FLK-1 and FLT-1) between IVTA-treated and sham-treated nondiabetic retinas (PVEGF-A = 0.2641, PFLK-1 = 0.4792, and PFLT-1 = 0.5222) (Fig. 2A-C).
###end p 65
###begin p 66
###xml 149 150 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 160 161 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 175 176 175 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 209 210 207 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 220 221 218 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Quantification analysis of VEGF-A, FLK-1, and FLT-1 distribution in the retina from different treatment groups. Number of positive cells for VEGF-A (A), FLK-1 (B), and FLT-1 (C) per millimeter (means +/- SEM, n = 8). ***P < 0.001.
###end p 66
###begin title 67
Retinal thickness analysis.
###end title 67
###begin p 68
###xml 143 144 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 156 162 151 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 162 163 157 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 168 169 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 342 343 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 354 360 344 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 360 363 350 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C&#8211;E</italic>
###xml 503 504 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 515 521 500 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 521 522 506 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
There was no significant difference in retinal thickness between IVTA- and sham-treated control eyes (147.28 +/- 1.23 vs. 147.60 +/- 1.40 mum, P = 0.8627) (Fig. 3A and B). There was a 10% reduction in the thickness of the IVTA-treated diabetic retinas compared with the sham-treated diabetic retinas (148.20 +/- 1.06 vs. 163.25 +/- 1.78 mum, P < 0.001) (Fig. 3C-E). Sham-treated diabetic retinas were significantly thicker than sham-treated nondiabetic retinas (163.25 +/- 1.78 vs. 147.60 +/- 1.40 mum, P < 0.001) (Fig. 3E).
###end p 68
###begin p 69
###xml 162 163 162 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 199 200 199 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 233 234 233 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 293 294 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 346 347 346 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 401 402 399 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Retinal thickness was measured on H&E-stained sections at the similar location. The micrograph shows representative samples from IVTA-treated nondiabetic retina (A), sham-treated nondiabetic retina (B), IVTA-treated diabetic retina (C), and sham-treated diabetic retina (D). The yellow bar in A demonstrates one measurement of retinal thickness. E: Table showing mean (+/- SEM) retinal thickness (*** P < 0.001). Original magnifications x200. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium layer; OS, inner and outer photoreceptor segment; CH, choroidal layer. To view a high-quality digital representation of this image, go to .
###end p 69
###begin title 70
The effect of IVTA on albumin leakage.
###end title 70
###begin p 71
###xml 143 149 143 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 149 150 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 155 156 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 309 315 309 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 315 316 315 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 318 319 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 322 323 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 329 330 329 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 485 486 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 498 504 494 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 504 505 500 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 722 723 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 735 741 727 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 741 742 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 892 893 880 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 905 911 893 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 911 912 899 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 202 206 <span type="species:ncbi:10116">rats</span>
Extravascular albumin was scarcely detected in the inner nuclear layer, outer nuclear layer, and outer plexiform layer of nondiabetic retinas (Fig. 4A and A1). In IVTA-treated and sham-treated diabetic rats, albumin leakage was observed mainly in the inner nuclear, outer plexiform, and outer nuclear layers (Fig. 4B, B1, C, and C1). There was 3.6-fold higher albumin expression in the sham-treated diabetic retinas than the nondiabetic controls (17.20 +/- 1.78 vs. 4.84 +/- 1.58 IAU, P < 0.0001) (Fig. 4D). However, albumin expression in the extravascular space was significantly reduced by 63.5% in IVTA-treated diabetic retinas compared with that in sham-treated diabetic retinas (6.27 +/- 0.46 vs. 17.20 +/- 1.78 IAU, P < 0.0001) (Fig. 4D). There was no difference between the IVTA-treated nondiabetic retinas versus sham-treated nondiabetic retinas (4.81 +/- 1.58 vs. 4.84 +/- 1.48 IAU, P = 0.9590) (Fig. 4D).
###end p 71
###begin p 72
###xml 148 149 148 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 301 302 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 445 446 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 481 482 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 510 511 510 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 514 515 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 522 523 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 550 551 550 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 553 554 553 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 560 561 560 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 641 642 641 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 646 647 646 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 780 781 778 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 791 792 789 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Immunohistochemical analysis of retinal albumin distribution. Albumin was detected (in red) within the vessels in sham-treated nondiabetic retinas (A). A similar pattern of albumin distribution was observed in IVTA-treated diabetic retina, but with slightly higher expression in extra vascular space (B). Diffuse extravascular albumin was observed in the inner nuclear, outer plexiform, and outer nuclear layers in sham-treated diabetic retina (C). Extravasated albumin (arrows in C) was marked green in panel A1, B1, and C1 (corresponding to panels A, B, and C) by IPP4.5. Intravascular albumin was excluded by the analysis (arrow heads in C1). D: Quantification of albumin distribution/leakage in the four treatment groups. Values were presented as IAU. Data are means +/- SEM, n = 8; *** P < 0.001. Original magnifications x400. To view a high-quality digital representation of this image, go to .
###end p 72
###begin title 73
DISCUSSION
###end title 73
###begin p 74
###xml 83 89 83 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegf-a</italic>
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flk-1</italic>
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flt-1</italic>
###xml 332 338 332 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegf-a</italic>
###xml 118 121 <span type="species:ncbi:10116">rat</span>
In this study, we have demonstrated that IVTA inhibits the increased expression of Vegf-a and Flk-1 in early diabetic rat retinas. By contrast, Flt-1 expression was decreased in early diabetic retinas but was upregulated following IVTA treatment. A strong correlation of albumin leakage and retinal thickness with the expression of Vegf-a and its receptors was observed. These findings indicate that one likely mechanism of action of IVTA on diabetic macular edema is through the differential regulation of VEGF-A and its receptors.
###end p 74
###begin p 75
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1015 1017 1015 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
VEGF-A is a major regulator of angiogenesis and vascular permeability in development and injury. The involvement of one of its receptors, FLK-1, in angiogenesis has been widely demonstrated (11), but few studies have addressed its role as a mediator of the BRB permeability. Ojima et al. (25) demonstrated that VEGF-induced FLK-1 phosphorylation and its downstream signaling cascade correlated with BRB breakdown and was inhibited by EphA2/ephrinA1 both in vitro and in vivo. In our study, the direct relationship between the expression of FLK-1 and the vascular permeability/breakdown of the BRB was further investigated in the diabetic retina. The overexpression of VEGF-A and FLK-1 that was found in the diabetic retina in this study, in association with increased albumin leakage, supports the hypothesis that FLK-1 is another important permeability factor and regulator of BRB dysfunction in diabetes. These data are consistent with a report that FLK-1 plays a critical role in breakdown of the brain barrier (26).
###end p 75
###begin p 76
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 991 996 991 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flt-1</italic>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 1107 1112 1107 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flt-1</italic>
###xml 1033 1036 <span type="species:ncbi:10116">rat</span>
The expression of another VEGF receptor, FLT-1, was unexpectedly decreased in diabetic retinas and increased following IVTA treatment. This may be a result of competition between FLK-1 and FLT-1. FLT-1 on endothelial cells may function as a negative regulator of FLK-1, acting as a so-called "decoy" receptor that regulates the activity of VEGFs on vascular endothelium by sequestering VEGF-A and thus rendering it less available to bind to FLK-1 (27). It is speculated that triggering of FLT-1 induces weak or undetectable ligand-dependent tyrosine phosphorylation in porcine aortic endothelial cells, whereas FLK-1 binding induces a strong response (28). Furthermore, VEGF-A mutants that bind selectively to FLK-1 are able to induce mitogenesis and chemotaxis in endothelial cells, and vascular permeability and angiogenesis in vivo, whereas VEGF-A mutants that selectively bind to FLT-1 do not have the activities stated above (29,30). In contrast to our finding, increased expression of Flt-1 in the 6-month STZ-induced diabetic rat retinas was reported by Hammes et al. (31). In their study, increased Flt-1 mRNA levels detected by in situ hybridization were found in the ganglion cell and both nuclear layers of diabetic samples only. This apparent discrepancy may be explained by the different durations of diabetes studied.
###end p 76
###begin p 77
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 61 66 <span type="species:ncbi:9606">human</span>
Diabetic macular edema is consistently reduced after IVTA in human clinical trials, as is sensitively demonstrated by Optical Coherence Tomography (32). In this study, the reduction of VEGF-A levels by IVTA treatment that we observed is consistent with a reduction in levels of extravasated albumin from the retinal vessels. This provides strong evidence that anti-VEGF therapy is an effective strategy for diabetic BRB dysfunction. Indeed, a recent phase II study suggested that the VEGF-A inhibitor, pegaptanib sodium, may also be efficacious in the treatment of diabetic macular edema (12).
###end p 77
###begin p 78
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 905 907 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
Two hypotheses have been proposed to explain the clinically established beneficial effect of corticosteroids on diabetic macular edema and the restoration of the BRB. Firstly, corticosteroids may inhibit VEGF-A signaling by blocking cytokine production, inducing leukocyte apoptosis (33), and, secondly, corticosteroids can directly induce the barrier properties of interendothelial tight junction complexes (34). A recent study suggests that corticosteroids may have relatively rapid effects, such as a decrease in paracellular flux and an increase in transepithelial resistance, which correlates with an increase in tight junction immunoreactivity at the cell border. A concomitant decrease in occludin phosphorylation, potentially countering the effects of VEGF-A, has also been noted (35). Steroid treatment also appears to increase the expression of at least some tight junction-associated proteins (36).
###end p 78
###begin p 79
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1070 1072 1070 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1304 1306 1304 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 1464 1466 1464 1466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 1701 1703 1701 1703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 1552 1560 <span type="species:ncbi:9606">patients</span>
By providing a deeper understanding of the mechanisms of action of intravitreal steroids on retinal disease, the results of this study may be used to refine their clinical use. In a placebo-controlled, randomized clinical trial, IVTA treatment doubled the chance of vision improvement and halved the risk of further loss in eyes with advanced diabetic macular edema. However, there was a significant risk of local adverse events, with 55% of eyes requiring surgery to remove cataract over 2 years and 44% requiring eye drops to control elevated intraocular pressure (18). Anti-VEGF antibodies are another potential treatment for diabetic retinopathy. Ranibizumab (37,38) and pegaptanib sodium (13) have already been approved in the U.S. for treatment of subretinal neovascularization; they are currently in advanced clinical development for diabetic retinopathy, and more specific VEGF inhibitors are in the pipeline. Presently, one of the disadvantages of these drugs is that they need to be injected every 4-6 weeks, as compared with every 6 months for triamcinolone (18). However, it is likely that longer-acting preparations will appear in due course. While VEGF inhibitors do not cause corticosteroid-associated side effects, they may confer an increased risk of systematic vascular adverse events (39). There is also a suspicion that VEGF inhibitors may eventually cause retinal atrophy by blocking the cytokine's recently discovered neuroprotective action (40). On the other hand, an increase in systemic adverse events has not been detected in patients receiving intravitreal steroid therapy, and there is some evidence to suggest that steroids may have a protective effect on photoreceptors (41), which could potentially offset any neurotoxic effect it might have through inhibiting VEGF-A. How the known adverse events of steroids will balance against the as yet largely unknown safety profile of specific VEGF inhibitors is a subject that warrants careful clinical research in future, as does the issue as to whether a long-acting steroid combined with a specific VEGF inhibitor in low doses might deliver the safest and most efficacious clinical response.
###end p 79
###begin p 80
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
The integrity of the BRB can be assessed by various techniques, each of which has advantages and limitations (42). Extravasated albumin has been demonstrated to be a precise indicator of the permeability of the blood-retinal and blood-brain barriers (21,43). IPP is a sensitive image analysis system that has been used to quantify subtle changes in a number of studies (24,44). In this study, immunolocalization of extravasated albumin was identified at the light microscopic level and quantified using IPP, providing a useful technique with which to study the effect of IVTA on DR.
###end p 80
###begin p 81
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 387 393 <span type="species:ncbi:9606">humans</span>
Rodent models do not mimic all aspects of human diabetes, but such models are essential for the development of new therapeutic approaches. While the short duration of diabetic injury in this model (3.5 weeks) imposes some limitations on the interpretation of the data, similar findings relating to the function of VEGF-A and its receptors on the BRB breakdown have also been observed in humans with diabetes, providing justification for our studies in rodents (45).
###end p 81
###begin p 82
This study adduces data that support the hypothesis that intravitreal corticosteroid treatment improves diabetic retinal edema by regulating the pathological expression of VEGF-A and its receptors. We also show that IVTA does not alter physiological VEGF-A, FLK-1, and FLT-1 levels in the normal retina. This raises the possibility that combination therapy of low-dose anti-VEGF drugs and steroids may offer advantages over anti-VEGF drugs alone for the treatment of DR that is resistant to conventional management.
###end p 82
###begin p 83
M.C.G. is included as an inventor on patents relating to the formulation of triamcinolone for ocular use and its use for the treatment of retinal neovascularization, but not macular edema. M.C.G. is an advisor and receives research support from Allergan (Posurdex).
###end p 83
###begin p 84
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 84
###begin p 85
###xml 0 3 0 3 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G1">AMD</term>
###xml 3 35 3 35 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="86">age-related macular degeneration</p>
###xml 3 35 3 35 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="86">age-related macular degeneration</p></def>
###xml 0 35 0 35 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G1">AMD</term><def><p textid="86">age-related macular degeneration</p></def></def-item>
###xml 35 38 35 38 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G2">AEC</term>
###xml 38 72 38 72 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="87">3-amino-9-ethylcarbazole chromogen</p>
###xml 38 72 38 72 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="87">3-amino-9-ethylcarbazole chromogen</p></def>
###xml 35 72 35 72 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G2">AEC</term><def><p textid="87">3-amino-9-ethylcarbazole chromogen</p></def></def-item>
###xml 72 75 72 75 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G3">BRB</term>
###xml 75 96 75 96 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="88">blood-retinal barrier</p>
###xml 75 96 75 96 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="88">blood-retinal barrier</p></def>
###xml 72 96 72 96 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G3">BRB</term><def><p textid="88">blood-retinal barrier</p></def></def-item>
###xml 96 99 96 99 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G4">DAB</term>
###xml 99 115 99 115 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="89">diaminobenzidine</p>
###xml 99 115 99 115 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="89">diaminobenzidine</p></def>
###xml 96 115 96 115 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G4">DAB</term><def><p textid="89">diaminobenzidine</p></def></def-item>
###xml 115 117 115 117 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G5">DR</term>
###xml 117 137 117 137 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="90">diabetic retinopathy</p>
###xml 117 137 117 137 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="90">diabetic retinopathy</p></def>
###xml 115 137 115 137 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G5">DR</term><def><p textid="90">diabetic retinopathy</p></def></def-item>
###xml 137 140 137 140 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G6">FLK</term>
###xml 140 158 140 158 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="91">fetal liver kinase</p>
###xml 140 158 140 158 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="91">fetal liver kinase</p></def>
###xml 137 158 137 158 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G6">FLK</term><def><p textid="91">fetal liver kinase</p></def></def-item>
###xml 158 161 158 161 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G7">FLT</term>
###xml 161 185 161 185 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="92">fms-like tyrosine kinase</p>
###xml 161 185 161 185 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="92">fms-like tyrosine kinase</p></def>
###xml 158 185 158 185 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G7">FLT</term><def><p textid="92">fms-like tyrosine kinase</p></def></def-item>
###xml 185 188 185 188 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G8">IAU</term>
###xml 188 208 188 208 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="93">image arbitrary unit</p>
###xml 188 208 188 208 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="93">image arbitrary unit</p></def>
###xml 185 208 185 208 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G8">IAU</term><def><p textid="93">image arbitrary unit</p></def></def-item>
###xml 208 211 208 211 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G9">IPP</term>
###xml 211 225 211 225 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="94">Image-Pro Plus</p>
###xml 211 225 211 225 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="94">Image-Pro Plus</p></def>
###xml 208 225 208 225 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G9">IPP</term><def><p textid="94">Image-Pro Plus</p></def></def-item>
###xml 225 229 225 229 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G10">IVTA</term>
###xml 229 278 229 278 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="95">intravitreal injection of triamcinolone acetonide</p>
###xml 229 278 229 278 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="95">intravitreal injection of triamcinolone acetonide</p></def>
###xml 225 278 225 278 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G10">IVTA</term><def><p textid="95">intravitreal injection of triamcinolone acetonide</p></def></def-item>
###xml 278 281 278 281 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G11">PFA</term>
###xml 281 297 281 297 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="96">paraformaldehyde</p>
###xml 281 297 281 297 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="96">paraformaldehyde</p></def>
###xml 278 297 278 297 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G11">PFA</term><def><p textid="96">paraformaldehyde</p></def></def-item>
###xml 297 301 297 301 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G12">qPCR</term>
###xml 301 339 301 339 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="97">quantitative polymerase chain reaction</p>
###xml 301 339 301 339 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="97">quantitative polymerase chain reaction</p></def>
###xml 297 339 297 339 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G12">qPCR</term><def><p textid="97">quantitative polymerase chain reaction</p></def></def-item>
###xml 339 343 339 343 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G13">REST</term>
###xml 343 376 343 376 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="98">relative expression software tool</p>
###xml 343 376 343 376 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="98">relative expression software tool</p></def>
###xml 339 376 339 376 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G13">REST</term><def><p textid="98">relative expression software tool</p></def></def-item>
###xml 376 379 376 379 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G14">STZ</term>
###xml 379 393 379 393 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="99">streptozotocin</p>
###xml 379 393 379 393 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="99">streptozotocin</p></def>
###xml 376 393 376 393 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G14">STZ</term><def><p textid="99">streptozotocin</p></def></def-item>
###xml 393 395 393 395 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G15">TA</term>
###xml 395 418 395 418 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="100">triamcinolone acetonide</p>
###xml 395 418 395 418 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="100">triamcinolone acetonide</p></def>
###xml 393 418 393 418 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G15">TA</term><def><p textid="100">triamcinolone acetonide</p></def></def-item>
###xml 418 421 418 421 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G16">TBS</term>
###xml 421 441 421 441 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="101">Tris-buffered saline</p>
###xml 421 441 421 441 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="101">Tris-buffered saline</p></def>
###xml 418 441 418 441 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G16">TBS</term><def><p textid="101">Tris-buffered saline</p></def></def-item>
###xml 441 444 441 444 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G17">UDG</term>
###xml 444 466 444 466 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="102">uracil-DNA glycosylase</p>
###xml 444 466 444 466 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="102">uracil-DNA glycosylase</p></def>
###xml 441 466 441 466 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G17">UDG</term><def><p textid="102">uracil-DNA glycosylase</p></def></def-item>
###xml 466 470 466 470 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G18">VEGF</term>
###xml 470 505 470 505 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="103">vascular endothelial growth factor.</p>
###xml 470 505 470 505 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="103">vascular endothelial growth factor.</p></def>
###xml 466 505 466 505 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G18">VEGF</term><def><p textid="103">vascular endothelial growth factor.</p></def></def-item>
###xml 0 505 0 505 <def-list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><def-item><term id="G1">AMD</term><def><p textid="86">age-related macular degeneration</p></def></def-item><def-item><term id="G2">AEC</term><def><p textid="87">3-amino-9-ethylcarbazole chromogen</p></def></def-item><def-item><term id="G3">BRB</term><def><p textid="88">blood-retinal barrier</p></def></def-item><def-item><term id="G4">DAB</term><def><p textid="89">diaminobenzidine</p></def></def-item><def-item><term id="G5">DR</term><def><p textid="90">diabetic retinopathy</p></def></def-item><def-item><term id="G6">FLK</term><def><p textid="91">fetal liver kinase</p></def></def-item><def-item><term id="G7">FLT</term><def><p textid="92">fms-like tyrosine kinase</p></def></def-item><def-item><term id="G8">IAU</term><def><p textid="93">image arbitrary unit</p></def></def-item><def-item><term id="G9">IPP</term><def><p textid="94">Image-Pro Plus</p></def></def-item><def-item><term id="G10">IVTA</term><def><p textid="95">intravitreal injection of triamcinolone acetonide</p></def></def-item><def-item><term id="G11">PFA</term><def><p textid="96">paraformaldehyde</p></def></def-item><def-item><term id="G12">qPCR</term><def><p textid="97">quantitative polymerase chain reaction</p></def></def-item><def-item><term id="G13">REST</term><def><p textid="98">relative expression software tool</p></def></def-item><def-item><term id="G14">STZ</term><def><p textid="99">streptozotocin</p></def></def-item><def-item><term id="G15">TA</term><def><p textid="100">triamcinolone acetonide</p></def></def-item><def-item><term id="G16">TBS</term><def><p textid="101">Tris-buffered saline</p></def></def-item><def-item><term id="G17">UDG</term><def><p textid="102">uracil-DNA glycosylase</p></def></def-item><def-item><term id="G18">VEGF</term><def><p textid="103">vascular endothelial growth factor.</p></def></def-item></def-list>
AMDage-related macular degenerationAEC3-amino-9-ethylcarbazole chromogenBRBblood-retinal barrierDABdiaminobenzidineDRdiabetic retinopathyFLKfetal liver kinaseFLTfms-like tyrosine kinaseIAUimage arbitrary unitIPPImage-Pro PlusIVTAintravitreal injection of triamcinolone acetonidePFAparaformaldehydeqPCRquantitative polymerase chain reactionRESTrelative expression software toolSTZstreptozotocinTAtriamcinolone acetonideTBSTris-buffered salineUDGuracil-DNA glycosylaseVEGFvascular endothelial growth factor.
###end p 85
###begin p 86
age-related macular degeneration
###end p 86
###begin p 87
3-amino-9-ethylcarbazole chromogen
###end p 87
###begin p 88
blood-retinal barrier
###end p 88
###begin p 89
diaminobenzidine
###end p 89
###begin p 90
diabetic retinopathy
###end p 90
###begin p 91
fetal liver kinase
###end p 91
###begin p 92
fms-like tyrosine kinase
###end p 92
###begin p 93
image arbitrary unit
###end p 93
###begin p 94
Image-Pro Plus
###end p 94
###begin p 95
intravitreal injection of triamcinolone acetonide
###end p 95
###begin p 96
paraformaldehyde
###end p 96
###begin p 97
quantitative polymerase chain reaction
###end p 97
###begin p 98
relative expression software tool
###end p 98
###begin p 99
streptozotocin
###end p 99
###begin p 100
triamcinolone acetonide
###end p 100
###begin p 101
Tris-buffered saline
###end p 101
###begin p 102
uracil-DNA glycosylase
###end p 102
###begin p 103
vascular endothelial growth factor.
###end p 103
###begin title 104
ACKNOWLEDGMENTS
###end title 104
###begin p 105
X.Z. is supported by a "University of Sydney-China Scholarship Council" scholarship. The study was also supported by the Lowy Medical Research Institute.
###end p 105
###begin p 106
Preliminary data were presented at the Australian Ophthalmic and Vision Science Meeting, December 2005.
###end p 106
###begin p 107
The authors appreciate the technical assistance provided by the Histopathology Laboratory, Discipline of Pathology, University of Sydney.
###end p 107
###begin title 108
REFERENCES
###end title 108
###begin article-title 109
Diabetic retinopathy and high blood pressure: defining the risk.
###end article-title 109
###begin article-title 110
Effects of asprin treatment on diabetic retinopathy ETDRS report number 8.
###end article-title 110
###begin article-title 111
Diabetic macular edema: passive and active transport of fluorescein through the blood-retina barrier.
###end article-title 111
###begin article-title 112
###xml 73 78 <span type="species:ncbi:9606">human</span>
Probenecid inhibition of the outward transport of fluorescein across the human blood-retina barrier.
###end article-title 112
###begin article-title 113
###xml 93 97 <span type="species:ncbi:10116">rats</span>
Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats.
###end article-title 113
###begin article-title 114
Sensitive blood-retinal barrier breakdown quantitation using Evans blue.
###end article-title 114
###begin article-title 115
VEGF-initiated blood-retinal barrier breakdown in early diabetes.
###end article-title 115
###begin article-title 116
###xml 72 77 <span type="species:ncbi:9606">human</span>
Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy.
###end article-title 116
###begin article-title 117
###xml 37 52 <span type="species:ncbi:10090">transgenic mice</span>
Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium.
###end article-title 117
###begin article-title 118
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium.
###end article-title 118
###begin article-title 119
The role of VEGF receptors in angiogenesis; complex partnerships.
###end article-title 119
###begin article-title 120
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
###end article-title 120
###begin article-title 121
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
###end article-title 121
###begin article-title 122
Intravitreal injection of triamcinolone for diffuse diabetic macular edema.
###end article-title 122
###begin article-title 123
Intravitreal triamcinolone for refractory diabetic macular edema.
###end article-title 123
###begin article-title 124
###xml 59 65 <span type="species:ncbi:9986">rabbit</span>
Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown.
###end article-title 124
###begin article-title 125
Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina.
###end article-title 125
###begin article-title 126
Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.
###end article-title 126
###begin article-title 127
###xml 122 125 <span type="species:ncbi:10116">rat</span>
The relation between expression of vasucular endothelial growth factor and breakdown of blood-retinal barrier in diabetic rat retina.
###end article-title 127
###begin article-title 128
###xml 96 100 <span type="species:ncbi:10116">rats</span>
In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats.
###end article-title 128
###begin article-title 129
###xml 91 95 <span type="species:ncbi:10116">rats</span>
Immunohistochemical detection of blood-retinal barrier breakdown in steptozotocin-diabetic rats.
###end article-title 129
###begin article-title 130
###xml 104 111 <span type="species:ncbi:9986">rabbits</span>
Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits.
###end article-title 130
###begin article-title 131
Evaluation of the Image-Pro Plus 4.5 software for automatic counting of labeled nuclei by PCNA immunohistochemistry.
###end article-title 131
###begin article-title 132
The role of interleukin-6 in mucosal IgA antibody responses in vivo.
###end article-title 132
###begin article-title 133
EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown.
###end article-title 133
###begin article-title 134
VEGFR-2 expression in brain injury: its distribution related to brain-blood barrier markers.
###end article-title 134
###begin article-title 135
Vascular endothelial growth factors and angiogenesis in eye disease.
###end article-title 135
###begin article-title 136
Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.
###end article-title 136
###begin article-title 137
Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): a reassessment using novel receptor-specific vascular endothelial growth factor mutants.
###end article-title 137
###begin article-title 138
Increased expression of angiogenic growth factors in age-related maculopathy.
###end article-title 138
###begin article-title 139
###xml 161 164 <span type="species:ncbi:10116">rat</span>
Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat.
###end article-title 139
###begin article-title 140
Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.
###end article-title 140
###begin article-title 141
Anti-inflammatory actions of glucocorticoids: molecular mechanisms.
###end article-title 141
###begin article-title 142
Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy.
###end article-title 142
###begin article-title 143
Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1: a potential mechanism for vascular permeability in diabetic retinopathy and tumors.
###end article-title 143
###begin article-title 144
Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin.
###end article-title 144
###begin article-title 145
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
###end article-title 145
###begin article-title 146
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
###end article-title 146
###begin article-title 147
Ranibizumab for neovascular age-related macular degeneration.
###end article-title 147
###begin article-title 148
Inhibitors of ocular neovascularization: promises and potential problems.
###end article-title 148
###begin article-title 149
Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor.
###end article-title 149
###begin article-title 150
Assessment of blood-retinal barrier integrity.
###end article-title 150
###begin article-title 151
###xml 131 135 <span type="species:ncbi:10116">rats</span>
The relationship between erythropoietin pretreatment with blood-brain barrier and lipid peroxidation after ischemia/reperfusion in rats.
###end article-title 151
###begin article-title 152
###xml 164 171 <span type="species:ncbi:9986">rabbits</span>
Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits.
###end article-title 152
###begin article-title 153
Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.
###end article-title 153

